<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Lubeluzole is a neuroprotective compound in the final stages of clinical evaluation </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the effects of intravenous followed by intraperitoneal doses of lubeluzole on histological outcome after reversible tandem middle cerebral/common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> in Long-Evans rats, with particular emphasis on the time window of efficacy </plain></SENT>
<SENT sid="2" pm="."><plain>Lubeluzole, started 15 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, had no adverse physiological or behavioral effects and reduce maximal <z:mpath ids='MPATH_124'>infarct</z:mpath> volume produced by 120 min or more of <z:mp ids='MP_0006134'>arterial occlusion</z:mp> by approximately 50%, from 143.2 +/- 11.8 mm3 (p &lt; 0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>Lubeluzole did not prolong the duration of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> which could be tolerated before histological damage occurred </plain></SENT>
<SENT sid="4" pm="."><plain>Lubeluzole was still effective if started 30 min after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (34% reduction of maximal <z:mpath ids='MPATH_124'>infarct</z:mpath> volume; p &lt; 0.05), but not after delays of 60 or 120 min. we conclude that lubeluzole has promise as a neuroprotective drug, particularly for more severe <z:hpo ids='HP_0001297'>strokes</z:hpo>, but must be started very rapidly after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> to be effective </plain></SENT>
</text></document>